Illustratief endocrinologisch laboratorium met monsterbuizen en analyseapparatuur bij CJC-1295 met DAC.

CJC-1295 with DAC: human study of GH and IGF-1 response

This Research Library page summarizes independently published research on CJC-1295. For each study, the research model, key finding, and main limitation are stated.

Study 1

Level of evidence: Human research - dose escalation

Subject: Pharmacokinetics, pharmacodynamics, and short-term safety of CJC-1295 with DAC.

Key finding: Sustained increases in GH and IGF-1 were measured after administration.

Main limitation: Small, short-term study; no evidence of muscle growth, fat loss, anti-aging effects, or long-term safety. CJC-1295 with DAC is not the same as no DAC.

Source: Original publication via PubMed

Study 2

Level of evidence: Human research - small clinical study

Subject: GH pulsatility after CJC-1295 with DAC.

Key finding: According to the measurements, the natural pulse pattern remained present while GH secretion was stimulated.

Main limitation: Very small study, men only, and no clinical endpoints.

Source: Original publication via PubMed


Scientific disclaimer: Research on a molecule, research model, or pharmaceutical formulation does not constitute evidence of the efficacy, safety, purity, or suitability of a commercial Peptidera product. This page does not contain treatment or usage advice.

Header image: illustrative visualization, not a research result.

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.